ENZYMATICA
Enzymatica is a life science company whose business concept is to offer effective help against some of our most common diseases where viruses or bacteria play a decisive role. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. Since launch the product has become one of the leading articles for colds in Swedish pharmacies. Development includes medical devices in upper respiratory infections and oral health, and veterinary products. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North.
ENZYMATICA
Industry:
Health Care Medical Device
Founded:
2007-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.enzymatica.com
Total Employee:
11+
Status:
Active
Contact:
+46 20 14 20 15
Total Funding:
20 M SEK
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Nginx Euro Microsoft Exchange Online
Similar Organizations
Ciegus
The company's business area is the development, manufacture and sale of equipment and services.
Current Advisors List
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-01-28 | Zymetech | Zymetech acquired by Enzymatica | N/A |
Investors List
Björn Algkvist
Björn Algkvist investment in Debt Financing - Enzymatica
MATS ANDERSSON
MATS ANDERSSON investment in Debt Financing - Enzymatica
HÃ¥kan Roos
HÃ¥kan Roos investment in Debt Financing - Enzymatica
Official Site Inspections
http://www.enzymatica.com
- Host name: 52.174.176.76
- IP address: 52.174.176.76
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091
More informations about "Enzymatica"
Organisation - Enzymatica
Dec 31, 2024 Holdings in Enzymatica: 27,574 shares and 100,000 warrants. Anja Trägårdh. Communications Manager since 2024 – Co-opted to the management team. Born 1978. Anja has been hired as the communication …See details»
Board of Directors - Enzymatica
In 2022, Enzymatica’s Board of Directors held 20 meetings at which the minutes were recorded, 7 of which were digital and 6 per capsulam. The meetings have touched on the company's …See details»
Home - Enzymatica
Feb 18, 2025 Interim report Q2/2024: Enzymatica builds momentum for expansion. All reports. financial calendar. April 10, 2025. Annual report 2024. Download to calendar. April 29, 2025. Interim report Jan-Mar 2025. Download …See details»
Enzymatica - Crunchbase Company Profile & Funding
Enzymatica is a life science company whose business concept is to offer effective help against some of our most common diseases where viruses or bacteria …See details»
Enzymatica AB: Shareholders Board Members Managers and …
Enzymatica AB: Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nasdaq Stockholm: ENZY | Nasdaq ...See details»
Enzymatica AB Year-end report 2024: Strong performance in core …
Feb 18, 2025 Enzymatica strengthened the sales organization by recruiting a new Senior Sales & Marketing Director Sweden, as well as a Director of Strategic Partnerships. ColdZyme …See details»
Enzymatica rang in the company at Nasdaq First North
Jun 15, 2015 Fredrik Lindberg, CEO, Enzymatica AB Phone: +46 708 86 53 70 | Email: [email protected] Lennart Nilsson, Chairman of the Board, Enzymatica AB …See details»
Enzymatica publishes supplementary prospectus - Yahoo Finance
Aug 18, 2022 The Board of Directors of Enzymatica AB ("Enzymatica" or "Company") has issued a supplement (the "Supplementary Prospectus") in addition to the EU growth prospectus that …See details»
Enzymatica AB: Enzymatica - publication of the annual
Mar 28, 2018 Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that …See details»
History - Enzymatica
Enzymatica participated in the Global Health Summit in Geneva, and a rights issue was approved, raising SEK 126.5 million for expansion and loan repayment. In Q4, the organization …See details»
Enzymatica Company Profile - Craft
Oct 29, 2024 Enzymatica is a life science company that develops and sells medical devices for infection-related diseases. Its products are based on a barrier technology that includes marine …See details»
Enzymatica Management
Enzymatica's CEO is Claus Egstrand, appointed in Sep 2021, has a tenure of 3.08 years. total yearly compensation is SEK4.70M, comprised of 99.1% salary and 0.9% bonuses, including …See details»
Claus Egstrand takes office as CEO ahead of schedule
Sep 8, 2021 Claus Egstrand assumes his role as CEO of Enzymatica three months ahead of schedule and takes office on September 9, 2021. When Claus Egstrand was appointed new …See details»
Publication of prospectus regarding Enzymatica’s rights issue
Aug 26, 2024 Claus Egstrand, CEO, Enzymatica AB. Phone: +44 7780 22 8385 | Email: [email protected]. Enzymatica AB is headquartered in Lund, Sweden, and is …See details»
Introduction - Enzymatica
Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes …See details»
Enzymatica AB: Lower sales in Q2 but 31% increase for the first …
Jul 17, 2018 News. Today's news; US; Politics; World; Tech. Reviews and deals ; Audio ; Computing ; GamingSee details»
BioStock: Final study results - ColdZyme reduces illness duration …
Sep 12, 2024 An independent investigator-initiated study from the University of Kent demonstrates that Enzymatica’s mouth spray ColdZyme reduces the duration of upper …See details»
Hem - Enzymatica
Enzymatica fokuserar på produktutveckling baserad på den beprövade och patenterade barriärteknologin som förkylningsprodukten ColdZyme bygger på. Läs mer. hållbarhet. Hälsa …See details»
ENZYMATICA : Equity price detail and Historic charts - Sharecast.com
The latest ENZYMATICA : Equity price detail and Historic chartsSee details»
Enzymatica AB: Excellent volume growth for ColdZyme®
Enzymatica completed its acquisition of Icelandic company Zymetech effective April 1. Enzymatica completed its new share issue, raising SEK 60 million before issue expenses. H1 …See details»